Lipella Pharmaceuticals (LIPO) Competitors $0.62 -0.02 (-2.64%) As of 10:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. SNSE, MBIO, HOOK, MRKR, LSB, PCSA, PHXM, ALBT, GOVX, and CYCNShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Sensei Biotherapeutics (SNSE), Mustang Bio (MBIO), HOOKIPA Pharma (HOOK), Marker Therapeutics (MRKR), LakeShore Biopharma (LSB), Heatwurx (PCSA), PHAXIAM Therapeutics (PHXM), Avalon GloboCare (ALBT), GeoVax Labs (GOVX), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Its Competitors Sensei Biotherapeutics Mustang Bio HOOKIPA Pharma Marker Therapeutics LakeShore Biopharma Heatwurx PHAXIAM Therapeutics Avalon GloboCare GeoVax Labs Cyclerion Therapeutics Sensei Biotherapeutics (NASDAQ:SNSE) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Is SNSE or LIPO more profitable? Sensei Biotherapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Sensei Biotherapeutics' return on equity of -72.13% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sensei BiotherapeuticsN/A -72.13% -61.35% Lipella Pharmaceuticals -988.83%-224.08%-172.88% Do insiders and institutionals have more ownership in SNSE or LIPO? 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate SNSE or LIPO? Sensei Biotherapeutics currently has a consensus price target of $55.00, indicating a potential upside of 497.44%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sensei Biotherapeutics is more favorable than Lipella Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor SNSE or LIPO? In the previous week, Sensei Biotherapeutics had 3 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 3 mentions for Sensei Biotherapeutics and 0 mentions for Lipella Pharmaceuticals. Sensei Biotherapeutics' average media sentiment score of 1.26 beat Lipella Pharmaceuticals' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Sensei Biotherapeutics Positive Lipella Pharmaceuticals Neutral Which has preferable valuation and earnings, SNSE or LIPO? Lipella Pharmaceuticals has higher revenue and earnings than Sensei Biotherapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensei BiotherapeuticsN/AN/A-$30.16M-$21.31-0.43Lipella Pharmaceuticals$536.36K5.33-$5.02M-$3.43-0.18 Which has more risk and volatility, SNSE or LIPO? Sensei Biotherapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. SummarySensei Biotherapeutics beats Lipella Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86M$3.14B$5.70B$10.42BDividend YieldN/A2.42%5.78%4.69%P/E Ratio-0.1521.8275.6726.39Price / Sales5.33453.96540.28125.20Price / CashN/A43.2725.6730.68Price / Book0.399.7212.826.40Net Income-$5.02M-$52.86M$3.29B$276.69M7 Day Performance3.17%1.75%1.12%-0.28%1 Month Performance4.90%8.64%4.54%6.69%1 Year Performance-84.23%19.19%68.00%27.62% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals1.2773 of 5 stars$0.62-2.6%N/A-83.8%$2.86M$536.36K-0.154Gap DownSNSESensei Biotherapeutics4.7555 of 5 stars$9.08+1.5%$55.00+505.7%-20.8%$11.45MN/A-0.4340Positive NewsGap UpMBIOMustang Bio0.9324 of 5 stars$1.56-4.3%N/A-86.2%$11.29MN/A-0.02100Positive NewsHOOKHOOKIPA Pharma2.2251 of 5 stars$0.92-1.1%$4.50+389.1%-79.1%$11.21M$9.35M-0.16160Gap DownMRKRMarker Therapeutics3.8573 of 5 stars$0.85-5.2%$13.17+1,442.5%-67.2%$11.05M$6.59M-0.6260Positive NewsLSBLakeShore Biopharma1.1775 of 5 stars$0.53-33.0%N/A-93.7%$11.01M$85.67M0.00773High Trading VolumePCSAHeatwurx3.8065 of 5 stars$0.21+8.5%$1.00+366.6%-84.5%$10.79MN/A-0.0920Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ALBTAvalon GloboCare1.1812 of 5 stars$2.72-0.4%N/A-24.4%$10.45M$1.33M-0.145GOVXGeoVax Labs1.6703 of 5 stars$0.65-1.2%$8.50+1,209.3%-73.6%$10.34M$3.95M-0.3210Analyst ForecastCYCNCyclerion Therapeutics1.2802 of 5 stars$3.02-0.7%N/A-7.5%$10.09M$2M-4.0830Gap DownHigh Trading Volume Related Companies and Tools Related Companies SNSE Competitors MBIO Competitors HOOK Competitors MRKR Competitors LSB Competitors PCSA Competitors PHXM Competitors ALBT Competitors GOVX Competitors CYCN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIPO Stock Alerts